MyoVision Listed by medusa Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On April 30, 2024, MyoVision, a Seattle-based developer and manufacturer of medical equipment, was listed by the medusa ransomware group. Public reporting indicates that internal files totaling 18.61 GB were exfiltrated in a ransomware attack. The number of people affected remains unknown, and further specifics about the intrusion have not been disclosed.

The listing itself is a claim by the group rather than independent confirmation of every detail. For an organization whose products support clinical and research work on the human body—including developments used by NASA—the exposure of internal material raises clear questions about operational data, proprietary designs, and any associated records that may have been taken.

Inside the incident

According to the available record, MyoVision was named on the medusa leak site in connection with a ransomware attack in which internal files were exfiltrated. The volume of data cited is 18.61 GB. The date the listing was reported is April 30, 2024. No public detail has been provided on the initial access method, the duration of unauthorized presence, whether encryption was deployed alongside theft, or any negotiation or payment demands. The number of individuals whose information may have been involved is listed as unknown. Beyond the characterization of the material as internal files, the precise contents of the 18.61 GB have not been itemized in the reported facts.

Because the primary source of the claim is the threat actor’s own listing, independent verification of the full scope remains limited. Organizations in this position typically face pressure from both the technical impact of a ransomware event and the reputational and regulatory consequences of data leaving their control. At present, those wider effects for MyoVision have not been publicly detailed.

Who is medusa?

Medusa is a well-documented ransomware operation that has operated as a ransomware-as-a-service model. Groups of this type typically gain access to corporate networks, exfiltrate data, and then threaten to publish or auction the material on a dedicated leak site if a ransom is not paid. The double-extortion approach—combining encryption of systems with the threat of data release—has been a consistent feature of medusa’s public activity across multiple sectors.

Medusa has previously listed victims from healthcare, manufacturing, professional services, and other industries. Listings on its site are claims made by the group; they do not automatically constitute verified proof of every asserted detail. In this case, the group claims MyoVision as a victim and cites the exfiltration of internal files totaling 18.61 GB. No additional statements attributed specifically to medusa about MyoVision beyond that listing appear in the provided facts.

Who is MyoVision?

MyoVision was founded in 1989 and develops and manufactures medical equipment used for the study of the body. Public information notes that many of the company’s developments have been used by NASA. Its corporate office is located at 13545 Erickson Pl NE Ste 200, Seattle, Washington, 98125, United States. Organizations of this kind typically design, produce, and support specialized diagnostic or research devices, maintain technical documentation, supplier and customer relationships, and hold internal operational records.

Because the work involves medical and research equipment, the company sits at the intersection of healthcare technology and advanced instrumentation. A breach affecting such an entity can touch proprietary designs, quality and regulatory documentation, and any data linked to clinical or research partners. The presence of NASA-related work further underscores the sensitivity of technical and contractual material that may exist inside the organization.

What was likely exposed

The reported facts state that internal files were exfiltrated and that the total volume of data leakage is 18.61 GB. No further breakdown of file types, databases, or personal data categories has been disclosed. Exact contents therefore remain unconfirmed.

Companies that design and manufacture medical equipment commonly hold engineering drawings, software and firmware source material, test and validation records, quality-management documentation, supplier contracts, customer lists, and internal correspondence. If any of those categories were among the internal files taken, the exposure could include both intellectual property and business-sensitive information. Whether any personally identifiable information belonging to employees, clinicians, or research subjects was present is not stated in the available record and should not be assumed.

Why it matters

For individuals who may have had contact with MyoVision—employees, contractors, clinical partners, or research collaborators—the principal risk is that any personal or professional data contained in the internal files could later appear in secondary leaks or be misused for social engineering. Because the number of people affected is unknown and the precise data types are undisclosed, the concrete exposure for any single person cannot yet be measured.

For the organization itself, the loss of 18.61 GB of internal material can affect competitive position if proprietary designs or process documentation were included, complicate regulatory or contractual obligations, and require costly investigation, notification, and remediation work. Even when encryption is not confirmed, the mere fact of exfiltration creates ongoing uncertainty about what may surface later. The medical-equipment sector also carries heightened expectations around data integrity and supply-chain security, so any confirmed compromise can influence partner confidence and oversight scrutiny.

What to do if you're exposed

If you have reason to believe your information may have been among MyoVision’s internal files, begin by monitoring financial and email accounts for unusual activity and enable multi-factor authentication wherever it is available. Consider placing a fraud alert or credit freeze with the major credit bureaus if you suspect personal identifiers were involved. Retain any official notices you receive from the company or regulators, as they may contain specific guidance or deadlines. Because public detail on this incident remains limited, treat unsolicited contacts that reference the breach with caution and verify them through known official channels. Readers can also run a free exposure scan of their email address to check whether that address has already appeared in other known breach datasets, providing an additional early-warning signal while more information about this particular event develops.

AICompiled with AI assistance from public sources and published under our editorial standards.